Related Experiment Videos
Committed to memory: lineage choices for activated T cells.
Vaishali R Moulton1, Donna L Farber
1Department of Surgery, Division of Transplantation, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
Trends in Immunology
|May 11, 2006
Summary
The study proposes a new intersecting pathway model for memory T-cell generation, suggesting distinct but related routes for antigen-driven and homeostasis-driven differentiation. This model explains how memory T cells form heterogeneous subsets influenced by various in vivo factors.
Area of Science:
- Immunology
- Cellular Biology
Background:
- The precise mechanisms governing memory T-cell generation and the heterogeneity of T-cell subsets remain incompletely understood.
- Previous models favored a linear progression from effector cells to memory T cells, but alternative origins from naive or non-effector activated T cells have been observed.
Purpose of the Study:
- To propose and discuss evidence supporting a novel 'intersecting pathway' model for memory T-cell generation.
- To explain the heterogeneity observed in memory T-cell populations.
Main Methods:
- Review and synthesis of evidence from diverse studies on memory T-cell generation.
- Conceptual modeling based on existing immunological data.
Main Results:
- Evidence supports an 'intersecting pathway' model where antigen-driven effector differentiation and homeostasis-driven memory differentiation are distinct yet analogous.
- Antigen withdrawal during effector differentiation facilitates a transition to the memory pathway via a pre-memory intermediate.
- Factors such as homeostasis, migration, and in vivo persistence contribute to memory T-cell heterogeneity.
Conclusions:
- The intersecting pathway model offers a more comprehensive framework for understanding memory T-cell generation than linear models.
- This model integrates various observed phenomena, including direct memory formation and the role of antigen withdrawal.
- Understanding these pathways is crucial for comprehending adaptive immunity and developing targeted immunotherapies.